ClassID:

21149

A61K39/39541 - page 2 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells

Recent Application in this class:
#301
20200247883
2020-08-06

COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION

#302
20200237902
2020-07-30

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

#303
20200231690
2020-07-23

Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease

#304
20200231676
2020-07-23

METHODS OF TREATING TRANSPLANT REJECTION USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L

#305
20200206346
2020-07-02

Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses

#306
20200206345
2020-07-02

Localized immunosuppression of allografts for peripheral nerve repair

#307
20200206332
2020-07-02

Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

#308
20200200751
2020-06-25

Compositions and methods for detecting prostate cancer

#309
20200190208
2020-06-18

Polypeptides

#310
20200179515
2020-06-11

ANTIBODY FORMULATIONS

#311
20200172621
2020-06-04

Combination therapies of HDAC inhibitors and PD-1 inhibitors

#312
20200171150
2020-06-04

Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

#313
20200171148
2020-06-04

TREATMENT WITH ANTI-VEGF ANTIBODIES

#314
20200166521
2020-05-28

Methods of treating inflammatory and autoimmune diseases with natalizumab

#315
20200163899
2020-05-28

Functionalized Prussian blue nanoparticles, combination Prussian blue nanoparticle-based nano-immunotherapy and applications thereof

#316
20200140556
2020-05-07

Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy

#317
20200140555
2020-05-07

Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS

#318
20200140553
2020-05-07

Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder

#319
20200131271
2020-04-30

ANTIBODIES TO OPGL

#320
20200102396
2020-04-02

Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient

#321
20200101160
2020-04-02

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

#322
20200101157
2020-04-02

VITRO CELL CULTURE METHODS FOR BETA-THALASSEMIA USING ACTIVIN TYPE II RECEPTOR LIGAND TRAPS

#323
20200101079
2020-04-02

ANTICANCER COMBINATION THERAPY

#324
20200088730
2020-03-19

Kit for monitoring, detecting and staging GVHD

#325
20200088726
2020-03-19

Method for high throughput peptide-MHC affinity screening for TCR ligands

#326
20200087415
2020-03-19

HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS

#327
20200087395
2020-03-19

CD200R agonist antibodies and uses thereof

#328
20200078457
2020-03-12

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

#329
20200069673
2020-03-05

Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

#330
20200061055
2020-02-27

Compounds and methods for treating cancer

#331
20200048349
2020-02-13

Anti-CD3 antibodies and uses thereof

#332
20200046817
2020-02-13

Tumor treatment method with an individualized peptide vaccine

#333
20200040087
2020-02-06

Human antibodies to GFRα3 and methods of making thereof

#334
20200031930
2020-01-30

Drug delivery compositions and uses thereof

#335
20200010849
2020-01-09

VIRAL DELIVERY OF NEOANTIGENS

#336
20200010553
2020-01-09

PREVENTIVE OR THERAPEUTIC AGENT FOR HTLV-1 ASSOCIATED MYELOPATHY USING LOW-DOSE OF ANTI-CCR4 ANTIBODY

#337
20200010552
2020-01-09

THERAPIES BASED ON CONTROL OF REGULATORY T CELL STABILITY AND FUNCTION VIA A NEUROPILIN-1:SEMAPHORIN AXIS

#338
20200010538
2020-01-09

Methods of treating skin cancer by administering a PD-1 inhibitor

#339
20200009191
2020-01-09

Combination immune therapy and cytokine control therapy for cancer treatment

#340
20200002423
2020-01-02

METHOD OF ADMINISTERING AN ANTIBODY

#341
20200002409
2020-01-02

Compositions and methods for the removal of biofilms

#342
20190388548
2019-12-26

METHOD FOR PROVIDING OCULAR NEUROPROTECTION OR FOR PREVENTING, TREATING OR ALLEVIATING THE EFFECTS OF, AN OCULAR DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEATH

#343
20190382492
2019-12-19

Drug delivery compositions and uses thereof

#344
20190358257
2019-11-28

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#345
20190352643
2019-11-21

Transgenic mouse expressing amyloid precursor protein that has olfactory neuron degeneration

#346
20190352424
2019-11-21

ErbB2 signaling and nerve regeneration

#347
20190343852
2019-11-14

Compositions and methods for inhibiting arginase activity

#348
20190336599
2019-11-07

COMBINATION OF RAMUCIRUMAB AND MERESTINIB FOR USE IN TREATMENT OF COLORECTAL CANCER

#349
20190336528
2019-11-07

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#350
20190328874
2019-10-31

Compositions and methods of modulating anti-tumor immunity

#351
20190328757
2019-10-31

INTRATUMORAL VEIN-FORMATION PROMOTING AGENT

#352
20190328721
2019-10-31

METHOD OF ACTIVATING DENDRITIC CELLS

#353
20190322743
2019-10-24

Agonistic antibodies that bind CD40

#354
20190316134
2019-10-17

Combination comprising immunostimulatory oligonucleotides

#355
20190315871
2019-10-17

Methods of treating inflammatory and autoimmune diseases with natalizumab

#356
20190315867
2019-10-17

Anti-TIGIT antibodies

#357
20190314481
2019-10-17

Vaccines against HPV and HPV-related diseases

#358
20190314390
2019-10-17

EP4 inhibitors and use thereof

#359
20190309084
2019-10-10

Bispecific Polypeptides to GITR and CTLA-4

#360
20190307849
2019-10-10

METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS

#361
20190298762
2019-10-03

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#362
20190292267
2019-09-26

Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity

#363
20190290732
2019-09-26

Compositions and methods for treating clostridium difficile infection

#364
20190284290
2019-09-19

DR5 RECEPTOR AGONIST COMBINATIONS

#365
20190284155
2019-09-19

2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use

#366
20190276535
2019-09-12

ANTIGEN BINDING PROTEINS

#367
20190276534
2019-09-12

Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies

#368
20190276517
2019-09-12

Methods and compositions for treating melanoma

#369
20190275148
2019-09-12

CAMK2D antisense oligonucleotides and uses thereof

#370
20190275007
2019-09-12

Benzamide and active compound compositions and methods of use

#371
20190269775
2019-09-05

COMPOSITIONS AND METHODS OF TREATING CANCER

#372
20190269756
2019-09-05

CD47 blockade therapy by HDAC inhibitors

#373
20190269726
2019-09-05

NOVEL IMMUNOTHERAPEUTIC TREATMENTS FOR TUMOURS

#374
20190269714
2019-09-05

GLA monotherapy for use in cancer treatment

#375
20190263909
2019-08-29

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

#376
20190263889
2019-08-29

CD80 and CD86 binding protein compositions and uses thereof

#377
20190256602
2019-08-22

Binding molecules binding PD-L1 and LAG-3

#378
20190255058
2019-08-22

Methods of treating hematologic cancers

#379
20190247470
2019-08-15

Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy

#380
20190241670
2019-08-08

Monoclonal antibody and a method of use for the treatment of lupus

#381
20190241659
2019-08-08

BISPECIFIC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF

#382
20190233533
2019-08-01

Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38

#383
20190209682
2019-07-11

ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF

#384
20190201492
2019-07-04

Immunomodulation after locoregional anti-tumoral treatment

#385
20190201462
2019-07-04

Adenovirus and immunomodulator combination therapy

#386
20190194330
2019-06-27

Methods of sensitizing cancer to immunotherapy

#387
20190192562
2019-06-27

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#388
20190192561
2019-06-27

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#389
20190185563
2019-06-20

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

#390
20190160115
2019-05-30

Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

#391
20190153098
2019-05-23

Drug delivery compositions and uses thereof

#392
20190144552
2019-05-16

Nucleic acid molecules encoding antibodies to the human glucagon receptor

#393
20190144548
2019-05-16

Depletion of plasmacytoid dendritic cells

#394
20190134195
2019-05-09

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED DISEASES

#395
20190127464
2019-05-02

Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies

#396
20190125851
2019-05-02

Therapeutic compositions and methods with cytokine signaling immunomodulators

#397
20190117768
2019-04-25

Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

#398
20190112371
2019-04-18

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

#399
20190112349
2019-04-18

MODIFIED CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY

#400
20190106501
2019-04-11

Compositions and methods for CD20 immunotherapy

#401
20190091262
2019-03-28

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#402
20190083626
2019-03-21

Method of treating cancer with a biomaterial and a toll-like receptor agonist

#403
20190083592
2019-03-21

IMMUNOSTIMULATORY COMBINATIONS

#404
20190083530
2019-03-21

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#405
20190070289
2019-03-07

Combination cancer therapy

#406
20190070186
2019-03-07

Compositions and methods for immune-mediated cancer therapy

#407
20190062395
2019-02-28

IL-2 superagonists in combination with anti-PD-1 antibodies

#408
20190060451
2019-02-28

Antigen binding proteins that bind PD-L1

#409
20190054166
2019-02-21

Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent

#410
20190054145
2019-02-21

Methods of treating cancer cells expressing tumor-associated integrins

#411
20190048081
2019-02-14

Method for treating cancer

#412
20190046639
2019-02-14

Anti-tumor agent containing immunomodulator, and antitumor effect potentiator

#413
20190038745
2019-02-07

Methods and compositions for treatment of amyloid deposition diseases

#414
20190038601
2019-02-07

Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer

#415
20190030162
2019-01-31

Combination Therapies Employing GITR Binding Molecules

#416
20190022197
2019-01-24

MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES

#417
20190008959
2019-01-10

Localized immunosuppression of allografts for peripheral nerve repair

#418
20190008958
2019-01-10

Localized immunosuppression of allografts for peripheral nerve repair

#419
20190002575
2019-01-03

METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS

#420
20190002550
2019-01-03

Methods and compositions for treating multiple sclerosis

#421
20190000924
2019-01-03

Ameliorating systemic sclerosis with death receptor agonists

#422
20190000877
2019-01-03

Combined organ and hematopoietic cells for transplantation tolerance of HLA mismatched grafts

#423
20190000861
2019-01-03

Drug combination and its use in therapy

#424
20180369380
2018-12-27

Methods and Compositions for Treating Conditions of the Eye

#425
20180360860
2018-12-20

Compositions and methods for inhibiting arginase activity

#426
20180355042
2018-12-13

Combination therapies of HDAC inhibitors and PD-1 inhibitors

#427
20180355030
2018-12-13

METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH PATHOLOGICAL NEOVASCULARIZATION

#428
20180353603
2018-12-13

Combination therapy including tumor associated antigen binding antibodies

#429
20180353464
2018-12-13

COMPOSITION FOR BLOCKING ANGIOGENESIS

#430
20180346577
2018-12-06

TREATMENT OF NEUROINFLAMMATORY DISEASE

#431
20180346559
2018-12-06

Anti-cancer combination therapy

#432
20180344845
2018-12-06

Polynucleotides encoding anti-CD40 antibodies

#433
20180344810
2018-12-06

Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

#434
20180344766
2018-12-06

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#435
20180338941
2018-11-29

RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY

#436
20180311348
2018-11-01

Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition

#437
20180305459
2018-10-25

Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease

#438
20180305456
2018-10-25

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

#439
20180303922
2018-10-25

Regulatory T cell PD-1 modulation for regulating T cell effector immune responses

#440
20180298099
2018-10-18

T-Cell Recepter (TCR) Targeting Therapies for Immune-Mediated Adverse Drug Reactions (ADRs) and Other Conditions

#441
20180296614
2018-10-18

Combination treatment

#442
20180296561
2018-10-18

The Methods For Treatment Of Tumors

#443
20180282415
2018-10-04

Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer

#444
20180282402
2018-10-04

ANTI-HRS ANTIBODIES AND COMBINATON THERAPIES FOR TREATING CANCERS

#445
20180280508
2018-10-04

Anti-cancer vaccine combination

#446
20180280506
2018-10-04

Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof

#447
20180280423
2018-10-04

Compositions and methods for combating drug-resistant cancers

#448
20180273619
2018-09-27

Dosage regimen for MAdCAM antagonists

#449
20180265596
2018-09-20

Binding molecules with modified J-chain

#450
20180265587
2018-09-20

Pharmaceutical compositions comprising humanized anti-CCR4 IgG4 antibody

#451
20180265582
2018-09-20

Immunological reagents

#452
20180264108
2018-09-20

IMMUNOGLOBULIN-LIKE MOLECULES DIRECTED AGAINST FIBRONECTIN-EDA

#453
20180251767
2018-09-06

Combination comprising immunostimulatory oligonucleotides

#454
20180251562
2018-09-06

Antibody Fragments Against the Insulin Receptor and Uses Thereof to Treat Hypoglycemia

#455
20180251547
2018-09-06

Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies

#456
20180250336
2018-09-06

COMPOSITIONS AND METHODS OF ENHANCING ANTI-TUMOR RESPONSE USING HYBRID NEUTROPHILS

#457
20180243412
2018-08-30

ANTIBODIES TO POLYPHOSPHATE DECREASE CLOT FORMATION, DECREASE INFLAMMATION, AND IMPROVE SURVIVAL

#458
20180243337
2018-08-30

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#459
20180237532
2018-08-23

METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS

#460
20180236062
2018-08-23

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

#461
20180222982
2018-08-09

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1

#462
20180221488
2018-08-09

ANTIBODY FORMULATIONS

#463
20180221475
2018-08-09

METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY

#464
20180221410
2018-08-09

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#465
20180221409
2018-08-09

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#466
20180221395
2018-08-09

METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS

#467
20180221337
2018-08-09

Methods and compositions for treating metabolic reprogramming disorders

#468
20180214583
2018-08-02

PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER

#469
20180214546
2018-08-02

MODULATION OF SRPX2-MEDIATED ANGIOGENESIS

#470
20180214524
2018-08-02

NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION

#471
20180208652
2018-07-26

Anti-KIR antibodies, formulations, and uses thereof

#472
20180207267
2018-07-26

ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF

#473
20180207164
2018-07-26

COMBINATION THERAPIES FOR TREATING CANCERS

#474
20180201679
2018-07-19

Humanized anti-CD79b antibodies and immunoconjugates and methods of use

#475
20180193380
2018-07-12

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#476
20180193379
2018-07-12

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#477
20180187211
2018-07-05

Methods and compositions for combination immunotherapy

#478
20180179277
2018-06-28

Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination

#479
20180169240
2018-06-21

METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS

#480
20180169238
2018-06-21

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

#481
20180162943
2018-06-14

GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy

#482
20180161426
2018-06-14

In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps

#483
20180148497
2018-05-31

Bispecific molecules comprising an HIV-1 envelope targeting arm

#484
20180147280
2018-05-31

Method of averting opioid addiction

#485
20180147198
2018-05-31

COMBINATIONS OF PFKFB3 INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCER

#486
20180140682
2018-05-24

Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy

#487
20180133183
2018-05-17

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

#488
20180126012
2018-05-10

Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies

#489
20180118841
2018-05-03

Polypeptides

#490
20180118826
2018-05-03

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

#491
20180118814
2018-05-03

Multi-valent hepatitis B virus antigen binding molecules and uses thereof

#492
20180111999
2018-04-26

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

#493
20180111998
2018-04-26

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease

#494
20180111997
2018-04-26

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

#495
20180110731
2018-04-26

Hydrogel compositions and drug delivery systems comprising the same

#496
20180105597
2018-04-19

TGFbeta Receptor II Antibodies

#497
20180105592
2018-04-19

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease

#498
20180086837
2018-03-29

Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity

#499
20180086833
2018-03-29

INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE

#500
20180079817
2018-03-22

Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient

#501
20180078639
2018-03-22

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

#502
20180067129
2018-03-08

Compositions and Methods for Identifying and Modulating Metabolic Health

#503
20180066053
2018-03-08

Nucleic acids encoding agonistic antibodies that bind CD40

#504
20180057606
2018-03-01

METHODS OF TREATING MENINGIOMA

#505
20180057593
2018-03-01

MASKED ANTI-CD3 ANTIBODIES AND METHODS OF USE

#506
20180050105
2018-02-22

PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand

#507
20180030154
2018-02-01

Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof

#508
20180028651
2018-02-01

Combination therapy for treatment of coronary artery disease

#509
20180028613
2018-02-01

Aortopathy

#510
20180016343
2018-01-18

Methods for treating or preventing asthma by administering an IL-4R antagonist

#511
20180015160
2018-01-18

In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus-Like Particles

#512
20180002422
2018-01-04

Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents

#513
20180000851
2018-01-04

Combination tumor immunotherapy

#514
20170369572
2017-12-28

Anti-CD47 antibodies and uses thereof

#515
20170368138
2017-12-28

Method of treating cancer with a multiple integrin binding Fc fusion protein

#516
20170360927
2017-12-21

DIAGNOSING AND TREATING IGA NEPHROPATHY

#517
20170360836
2017-12-21

Combination immune therapy and cytokine control therapy for cancer treatment

#518
20170355774
2017-12-14

Anti-GITR antibodies and uses thereof

#519
20170354671
2017-12-14

TREATMENT OF OCULAR DISORDERS

#520
20170335324
2017-11-23

METHODS FOR TREATING NEURODEGENERATIVE DISEASES

#521
20170334993
2017-11-23

Treatment of pediatric BCP-ALL patients with an anti-KIR antibody

#522
20170327582
2017-11-16

Combination therapies of HDAC inhibitors and PD-1 inhibitors

#523
20170327573
2017-11-16

Composition to induce bone marrow stem cell mobilization

#524
20170281765
2017-10-05

Antigen binding proteins that bind PD-L1

#525
20170281764
2017-10-05

Antibodies to TIGIT

#526
20170266280
2017-09-21

Approach for treatment of cancer via immunomodulation by using talabostat

#527
20170258905
2017-09-14

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

#528
20170258901
2017-09-14

Localized immunosuppression of allografts for peripheral nerve repair

#529
20170258765
2017-09-14

Priming of pancreatic tumor cells and cancer stem cells to TRAIL-induced apoptosis

#530
20170247457
2017-08-31

Methods of treating inflammatory and autoimmune diseases with natalizumab

#531
20170240634
2017-08-24

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

#532
20170232099
2017-08-17

Therapy-enhancing glucan

#533
20170226205
2017-08-10

Therapeutic use of anti-CD22 antibodies for inducing trogocytosis

#534
20170216434
2017-08-03

COMPOSITIONS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE

#535
20170216433
2017-08-03

Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses

#536
20170216403
2017-08-03

SYNERGISTIC TUMOR TREATMENT WITH IL-2, A THERAPEUTIC ANTIBODY, AND AN IMMUNE CHECKPOINT BLOCKER

#537
20170210813
2017-07-27

Anti-PDGFR-beta antibodies and uses thereof

#538
20170209572
2017-07-27

Classifiers of NF-κB pathway activation, devices, and methods of use thereof

#539
20170204189
2017-07-20

Therapeutic method and medicament for HTLV-1 associated myelopathy

#540
20170204186
2017-07-20

Depletion of plasmacytoid dendritic cells

#541
20170202961
2017-07-20

Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection

#542
20170182161
2017-06-29

Antigen Binding Proteins that Bind PD-L1

#543
20170174768
2017-06-22

Depletion of plasmacytoid dendritic cells

#544
20170173151
2017-06-22

HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74

#545
20170173114
2017-06-22

METHODS AND COMPOSITIONS FOR INDUCTION OF UCP1 EXPRESSION

#546
20170173013
2017-06-22

Combination therapy for cancer

#547
20170165360
2017-06-15

Methods of treating autoimmune diseases

#548
20170165236
2017-06-15

SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH

#549
20170137524
2017-05-18

THERAPIES BASED ON CONTROL OF REGULATORY T CELL STABILITY AND FUNCTION VIA A NEUROPILIN-1:SEMAPHORIN AXIS

#550
20170137512
2017-05-18

KV1.3 binding immunoglobulins

#551
20170130228
2017-05-11

Compositions and methods to activate or inhibit toll-like receptor signaling

#552
20170129960
2017-05-11

Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels

#553
20170119877
2017-05-04

Use of vista agonists and antagonists to suppress or enhance humoral immunity

#554
20170119819
2017-05-04

Combined organ and hematopoietic cells for transplantation tolerance of grafts

#555
20170114132
2017-04-27

Use of negative functional modulators of erythropoietin for therapy

#556
20170106086
2017-04-20

Combined organ and hematopoietic cells for transplantation tolerance of HLA mismatched grafts

#557
20170106065
2017-04-20

Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3

#558
20170100329
2017-04-13

Method and system for preventing migraine headaches, cluster headaches and dizziness

#559
20170096409
2017-04-06

2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use

#560
20170095464
2017-04-06

METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF CERTAIN LEUKEMIAS

#561
20170037135
2017-02-09

Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

#562
20170029508
2017-02-02

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

#563
20170022276
2017-01-26

METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

#564
20170016900
2017-01-19

KIT FOR MONITORING, DETECTING AND STAGING GVHD

#565
20160376372
2016-12-29

Methods of treating multiple sclerosis using anti-CD20 antibodies

#566
20160375044
2016-12-29

Compositions and methods for inhibiting arginase activity

#567
20160340648
2016-11-24

Purification of functional human astrocytes

#568
20160340438
2016-11-24

CD37-binding molecules and immunoconjugates thereof

#569
20160333106
2016-11-17

Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody

#570
20160331825
2016-11-17

Vaccines against HPV and HPV-related diseases

#571
20160280790
2016-09-29

Depletion of plasmacytoid dendritic cells

#572
20160168257
2016-06-16

Molecules that bind CD180, compositions and methods of use

#573
20160158348
2016-06-09

Adjuvant combinations comprising alpha-galactosylceramide or iGb3, CD40 agonists and antigen

#574
20160130347
2016-05-12

Fc-free antibodies comprising two fab-fragments and methods of use

#575
20160129095
2016-05-12

Immunostimulatory combinations

#576
20160122433
2016-05-05

Anti-PDGFR-beta antibodies and uses thereof

#577
20160022777
2016-01-28

COMBINATION THERAPY WITH IL-12

#578
20160017037
2016-01-21

Anti-LAG-3 binding proteins

#579
20160009803
2016-01-14

Therapeutic methods using anti-CD200 antibodies

#580
20160008463
2016-01-14

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

#581
20160000909
2016-01-07

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

#582
20160000817
2016-01-07

Treatment of ocular disorders

#583
20150359905
2015-12-17

Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases

#584
20150359811
2015-12-17

GLA monotherapy for use in cancer treatment

#585
20150343024
2015-12-03

Method of inducing senescence in tumor cells by administrating TNF-a in combination with IFNa or IFNy

#586
20150337045
2015-11-26

Human antibodies to the glucagon receptor and methods of use thereof

#587
20150299316
2015-10-22

Compositions and methods including a recombinant human MAB that promotes CNS remyelination

#588
20150268243
2015-09-24

Methods for predicting the sensitivity of a subject to immunotherapy

#589
20150265591
2015-09-24

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

#590
20150216971
2015-08-06

Methods for treating GI syndrome and graft versus host disease

#591
20150197569
2015-07-16

Anti-KIR antibodies, formulations, and uses thereof

#592
20150196626
2015-07-16

Modulation of yeast-based immunotherapy products and responses

#593
20150165021
2015-06-18

COMBINATION THERAPY

#594
20150140072
2015-05-21

Aminoacyl tRNA synthetases for modulating inflammation

#595
20150140007
2015-05-21

PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING TYPE I DIABETES AND APPLICATION THEREOF

#596
20150104460
2015-04-16

Human Antibodies and Specific Binding Sequences Thereof for use in Stroke and Ischemia or Ischemic Conditions

#597
20150072927
2015-03-12

Methods and compositions to regulate hepcidin expression

#598
20150065781
2015-03-05

Combination therapy for the treatment of glioblastoma

#599
20150050289
2015-02-19

Method of treating motor neuron disease with an antibody that agonizes MuSK

#600
20150044164
2015-02-12

Methods of treating autoimmune diseases